For example, in TKI-pretreated patients with late stage NSCLC, the T790M mutation was found in 71% of urine cfDNA samples and in 75% of tissue samples, as assessed by the Trovagene quantitative PCR-NGS EGFR T790M assay and the Therascreen® EGFR RGQ polymerase chain reaction test, respectively. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.